Released: 13-Mar-2002 12:00 AM EST
Three New Targets Found for Cancer Vaccines
Ludwig Cancer Research

Investigators at the Ludwig Institute for Cancer Research have discovered three new genes that may prompt the immune system to seek out and destroy cancer cells.

22-May-2002 12:00 AM EDT
Targeted Cancer Vaccine May Help Immune System Fight Cancer
Ludwig Cancer Research

Phase I study suggests that a protein-based vaccine may safely activate anti-cancer defenses.

Released: 4-Jun-2002 12:00 AM EDT
Predictions on the Number of Human Genes Turn Out Wrong
Ludwig Cancer Research

Researchers discovered that chromosome 21 contains 10% more genes than earlier sequence efforts found, suggesting that if predictions on the smallest and most thoroughly analyzed chromosome are wrong, than humans have more genes than the favored 30,000 estimate.

13-Jun-2002 12:00 AM EDT
Genomic Book of Life May End Up with Missing Pages
Ludwig Cancer Research

Study suggests that current DNA chips need improvement to fully understand how genes work.

16-Jul-2002 12:00 AM EDT
New and Improved Web Site to Study Genes
Ludwig Cancer Research

Experts who utilize gene databases on the Internet face the same type of problems that greet many Web surfers, so some of them have designed an easier and more accurate way to search for potential disease-causing genes.

19-Jul-2002 12:00 AM EDT
One Molecular Switch May be Key to Fighting Several Diseases
Ludwig Cancer Research

Study in mice suggests that blocking one signaling pathway may help against autoimmune disease, transplant rejection, and leukemia.

Released: 17-Jul-2002 12:00 AM EDT
Measuring a Specific Immune Response to Detect Colon Cancer
Ludwig Cancer Research

In a step that might eventually make colon cancer easier to detect and treat, a study finds that the immune system naturally identifies the hallmark signs of this cancer.

29-Aug-2002 12:00 AM EDT
An Immune Cell's Dramatic Rescue Efforts Caught on Tape
Ludwig Cancer Research

A novel video technique exposes an unnoticed pathway that allows dormant immune cells to become active again, providing new insights on how the immune system might be harnessed to fight disease.

30-Sep-2002 12:00 AM EDT
New Yorkers Come Together to Discover New Ways to Fight Cancer
Ludwig Cancer Research

For the first time, investigators from six local New York medical centers are all working together to conduct a series of unique early-stage clinical trials on cancer vaccines.

14-Jan-2003 12:00 AM EST
Blocking One Protein Helps Cancer Cells Die of Natural Causes
Ludwig Cancer Research

A protein that hinders tumor fighting genes may be the key to new treatments for cancer.

Released: 31-Jan-2003 12:00 AM EST
Brazil Scientists Help Calfornia Wine
Ludwig Cancer Research

Brazilian researchers decipher genetic clues that may spell the end of a pest that threatens Californian wine.

Released: 1-Mar-2003 12:00 AM EST
How Dendritic Cells Grow Up to Take on Foreign Invaders
Ludwig Cancer Research

A study explains how cells crucial to the body's defense system can stimulate an immune response, raising new possibilities for their use in cancer vaccines.

16-Apr-2003 12:00 AM EDT
Firefly Light Helps Destroy Cancer Cells
Ludwig Cancer Research

Researchers find that the bioluminescence effects of fireflies may kill cancer cells from within.

Released: 16-Apr-2003 12:00 AM EDT
Adding a New Chapter to the DNA Book of Life
Ludwig Cancer Research

A study pushes the Human Genome Project one step forward, documenting the complete activity of genes found in both healthy and cancerous cells.

3-Jun-2003 12:00 AM EDT
Testing Different Vaccine Approaches to Defeat Cancer
Ludwig Cancer Research

Researchers study a range of vaccine strategies to harness the body's own natural ability to fight cancer. One patient seemingly helped by immune defenses alone.

11-Sep-2003 4:00 PM EDT
Finding Genetic Gold in the Amazon
Ludwig Cancer Research

Can the complete genetic sequence of a common bacterium found in the Amazon help save the rainforest?

16-Feb-2004 9:00 AM EST
First Integrated Immunological Response - Beacon for Cancer Vaccine Development
Ludwig Cancer Research

First study to demonstrate that vaccination with a cancer-specific recombinant protein antigen has successfully induced a fully integrated immunological response in humans.

1-Mar-2004 12:00 PM EST
Protein Sequences: Not So Predictable After All
Ludwig Cancer Research

Discovery of novel protein processing mechanism, proteasome-mediated post-translational splicing of peptides, which has implications for predicting protein sequence from gene sequence, and for monitoring immunological responses to cancer, and perhaps HIV, vaccines.

10-Apr-2004 9:00 AM EDT
SSX: A New Family of Cancer Vaccine Targets
Ludwig Cancer Research

Scientists from the Cancer Vaccine Collaborative (CVC) have discovered that the cancer-specific protein, SSX-2, induces a spontaneous immunological reaction against cancer cells in melanoma patients, offering a new target for the development of a therapeutic melanoma vaccine.

12-Apr-2004 4:50 PM EDT
How Cancer Neutralizes T Cell Attack
Ludwig Cancer Research

Investigators analyzed the function of CD8 T cells that recognize a cancer-specific antigen and found that the tumor and invaded lymph nodes are able to neutralize the function of cytotoxic CD8 T cells.

27-Apr-2004 2:30 PM EDT
Setting the Gene Expression Base-Line for Breast Cancer Research
Ludwig Cancer Research

While insights into breast cancer have been drawn from determining the expression 'profiles' of thousands of genes in tumors, the interpretation of experimental results has been complicated by the absence of knowledge about the gene expression in 'normal,' non-cancerous, breast cells.

Released: 6-May-2004 12:20 PM EDT
Second Generation Targeted Antibodies - It’s All in the Binding
Ludwig Cancer Research

Just weeks after one of the first anti-EGFR antibodies, ImClone's Erbitux (Cetuximab), was approved for use in Europe and the USA, the unique binding properties of a "˜second generation' anti-EGFR antibody from LICR have been elucidated.

19-Jul-2004 6:30 AM EDT
Vaccine Boosts Immunity Against Cancer Target
Ludwig Cancer Research

A therapeutic cancer vaccine being co-developed by the Ludwig Institute for Cancer Research and the Australian biotechnology company CSL Limited successfully induced a comprehensive immune response in patients and appeared to delay cancer recurrence.

Released: 21-Sep-2004 2:00 PM EDT
Cancer Vaccines 2004: a Report from the World
Ludwig Cancer Research

New findings in the development of cancer vaccines from the USA, Australia, Europe and Japan will be presented as part of the International Cancer Immunotherapy Symposia Series.

Released: 20-Oct-2004 4:20 PM EDT
P110 Delta: a Key Player in the Allergic Response
Ludwig Cancer Research

Findings from the University College London Branch of the Ludwig Institute for Cancer Research detail how inactivating a key signalling molecule called p110delta reduced the effect of allergies on mice.

28-Jan-2005 10:30 AM EST
Pathogen-Mimicking Vaccine as Strategy for Cancer Therapy
Ludwig Cancer Research

Results from the first clinical trial of a therapeutic cancer vaccine combining the synthetic bacterial DNA sequence, CpG 7909, with a peptide antigen were reported.

3-Mar-2005 9:20 AM EST
Yeast Network Prevents Damage by Oxygen Radicals
Ludwig Cancer Research

Scientists at the University of California, San Diego Branch of the Ludwig Institute for Cancer Research have identified a key network of DNA repair and cell cycle control genes in yeast that prevents the deleterious effects of radical oxygen species.

12-Apr-2005 1:35 PM EDT
Prostate Cancer Therapy -- New Molecular Screening Theory
Ludwig Cancer Research

Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published today by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).

2-Jun-2005 2:00 PM EDT
Cancer Research Finds Targets for New Cholesterol-Lowering Therapies
Ludwig Cancer Research

A team of investigators from the Uppsala Branch of the Ludwig Institute for Cancer Research and Harvard Medical School has uncovered novel targets for the development of drugs that would potentially complement, or replace, statins in treating heart disease.

27-Jun-2005 12:00 PM EDT
Whole Genome Promoter Mapping -- Human Genome Project v2.0?
Ludwig Cancer Research

Investigators have developed an efficient method to identify thousands of regulatory sequences in the human genome, according to a study.

20-Jul-2005 2:20 PM EDT
Unraveling a Stomach Cancer Puzzle
Ludwig Cancer Research

A multi-national research team led by the Melbourne Branch of the Ludwig Institute for Cancer Research has identified a potential new target for stomach cancer therapy, according to a paper published today.

11-Apr-2006 4:20 PM EDT
Diabetes and Cancer: Alpha Connection
Ludwig Cancer Research

A study in Nature has defined the function of p110 alpha PI3K, which is in one of the most frequently activated pathways in cancer. Using a new approach to generating mouse models investigators from the Ludwig Institute for Cancer Research and the UCL Centre for Diabetes & Endocrinology have uncovered important information for planned clinical trials.

4-Sep-2006 2:00 PM EDT
Protein Splicing Upsets the DNA Colinearity Paradigm
Ludwig Cancer Research

Colinearity of DNA and protein sequences is thought to be a fundamental feature of the universal genetic code. However, a paper published today in Science by a team from the Brussels Branch of the global Ludwig Institute for Cancer Research (LICR) and the Seattle-based Fred Hutchinson Cancer Research Center (FHCRC), shows that a protein can be rearranged so that it is no longer colinear with its encoding DNA.

Released: 26-Mar-2013 11:00 AM EDT
Ludwig Cancer Researchers Honored Among First Class of Fellows
Ludwig Cancer Research

Three Ludwig scientists were named as Fellows in the inaugural class of the AACR Academy, the most prestigious honor bestowed by the American Association for Cancer Research. The 106 Fellows were selected by their peers for their extraordinary contributions to the cancer field.

Released: 8-Apr-2013 9:00 AM EDT
A Hijacking of Healthy Cellular Circuits
Ludwig Cancer Research

In the current issue of Cancer Discovery, a team led by Paul Mischel at the Ludwig Institute for Cancer Research and Steven Bensinger at the University of California, Los Angeles, identifies a unique mechanism by which glioblastoma cells develop resistance to drugs that target EGFR signaling.

Released: 10-Apr-2013 10:00 AM EDT
Ludwig Presents Immunotherapy and Epigenetics at AACR
Ludwig Cancer Research

A dozen Ludwig scientists presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research Annual Meeting. Progress in immunotherapy and epigenetics led the program with important treatment implications for emerging cancer therapy.

Released: 21-Apr-2013 1:00 PM EDT
A Check on Tension
Ludwig Cancer Research

A recent study published by Ludwig scientists in Nature upends the model for how dividing cells monitor the equal distribution of their chromosomes—a process that often runs awry in cancer. By targeting Aurora B kinase, their discovery has overturned the prevailing model of advanced cell division.

Released: 25-Apr-2013 12:00 PM EDT
Reviving a Foe of Cancer
Ludwig Cancer Research

Cancer cells are a problem for the body because they multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong. One protein that keeps healthy cells from behaving this way is a tumor suppressor named p53. This protein stops potentially precancerous cells from dividing and induces suicide in those that are damaged beyond repair. Not surprisingly, p53’s critical function is disrupted in most cancers.

Released: 9-May-2013 12:00 PM EDT
Mapping the Embryonic Epigenome
Ludwig Cancer Research

A large, multi-institutional research team involved in the NIH Epigenome Roadmap Project has published a sweeping analysis in the current issue of the journal Cell of how genes are turned on and off to direct early human development.

Released: 30-May-2013 12:00 PM EDT
Ludwig Institute Appoints New Scientific Director
Ludwig Cancer Research

Professor Sir David Lane, an internationally recognized and respected cancer researcher widely known for his discovery of the p53 tumor suppressor protein, joins the Ludwig Institute for Cancer Research as its Scientific Director, commencing June 1, 2013.

Released: 2-Jun-2013 12:00 PM EDT
A One-Two Punch Against Cancer
Ludwig Cancer Research

A team of researchers led by Jedd Wolchok of the Ludwig Center at MSKCC presented data today at the ASCO Annual Meeting showing promising results from a Phase I clinical trial evaluating the concurrent use of two immunotherapies for the treatment of advanced melanoma.

Released: 12-Jun-2013 8:00 AM EDT
Immune Design Partners with Top Cancer Organizations
Ludwig Cancer Research

The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and Immune Design, a biotech company focused on immune-based therapies for cancer and other human diseases, today announced that they have signed a collaboration agreement to advance cancer immunotherapy research.

Released: 20-Jun-2013 12:00 PM EDT
Herding Cancer Cells to Their Death
Ludwig Cancer Research

An international team of scientists led jointly by the Ludwig Institute for Cancer Research and the University of Murcia describe a therapeutic strategy in today’s online issue of Cancer Cell that manipulates a mechanism driving cellular heterogeneity to treat advanced melanoma.

Released: 12-Aug-2013 12:00 PM EDT
New Insights Into Neuroblastoma Tumor Suppressor May Provide Clues for Improved Treatment
Ludwig Cancer Research

Loss of a gene required for stem cells in the brain to turn into neurons may underlie the most severe forms of neuroblastoma, a deadly childhood cancer of the nervous system, according to a Ludwig Cancer Research study published in Developmental Cell today.

19-Sep-2013 1:00 PM EDT
A Boost for Cellular Profiling
Ludwig Cancer Research

A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell—a capability of relevance to everything from basic research to future cancer diagnostics.

3-Oct-2013 6:00 PM EDT
A Genetic Variation That Could Protect Skin From Sun Damage Fuels Testicular Cancer
Ludwig Cancer Research

A Ludwig Cancer Research study published in Cell today identifies a common mutation that dramatically increases the risk for testicular cancer—and describes a likely molecular mechanism by which it exerts that effect.

Released: 21-Oct-2013 9:00 AM EDT
Targeting Cancer’s Sweet Tooth
Ludwig Cancer Research

Ludwig Cancer Researchers find that glioblastomas that rely predominantly on the mTORC2-mediated pathway tend to have the worse prognosis. Further, their studies suggest that lung cancer cells, too, use this pathway to induce the Warburg effect.

31-Oct-2013 12:00 PM EDT
Is DNA From Mom or Dad?
Ludwig Cancer Research

A new technique successfully takes on a longstanding challenge in DNA sequencing – determining whether a particular genetic sequence comes from an individual's mother or father. The method, described in a Ludwig Cancer Research study in Nature Biotechnology, promises to accelerate studies of how genes contribute to disease, improve the process of matching donors with organs and help scientists better understand human migration patterns.

2-Dec-2013 4:00 PM EST
Cancer’s Game of Hide-and-Seek
Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma (GBM), the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer. The findings could have far-reaching implications for the therapeutic regimens currently employed to treat GBM and suggest alternative approaches that could improve outcomes for cancer patients.

Released: 6-Jan-2014 7:00 AM EST
Ludwig Cancer Research Bestows Half a Billion in New Funding to Six Eminent U.S. Research Institutions
Ludwig Cancer Research

Cancer research in the U.S. got a critical boost today as the six Ludwig Centers at Johns Hopkins University, Harvard University, the Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center, Stanford University and the University of Chicago received a total of $540 million as part of a gift from Ludwig Cancer Research, on behalf of its founder, Daniel K. Ludwig. This new funding ranks among the largest private philanthropic gifts to cancer research.


close
1.05451